Grail and Veeva Systems could be well insulated from near-term headwinds.

Jim Cramer sees three stocks with very different amounts of bad news or good news already baked into

GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical

Adoption by insurers and FDA approval are critical for future performance. Profitability is not expe

UBS analyst Doug Schenkel maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target fr

Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) rose 5.5% during mid-day trading on Wednesday

Guggenheim analyst Subbu Nambi maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price targ

Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) hit a new 52-week high on Thursday. The compa

Grail's stock recently hit its all-time high. If the FDA approves Galleri, it still looks reasonably

The key to the company's future is medical insurers adopting Galleri. The FDA looks likely to grant

Canaccord Genuity analyst Kyle Mikson maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the pri

GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CFO Aaron Freidin sold 4,100 shares of the company's st

Mizuho analyst Bradley Bowers maintains GRAIL (NASDAQ:GRAL) with a Neutral and raises the price t

Grail's stock surged 55% after a favorable FDA committee vote, and ultimately, FDA approval could dr

The FDA advisory committee voted in favor of GRAIL's Galleri multi-cancer early detection test,

GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CEO Joshua Ofman sold 61,452 shares of the firm's stock

There are many unrecognized trade-offs to home ownership that can make renting a better economic cho

The FDA is expected to make its final ruling on Galleri's premarket approval in the coming months.

SUNNYVALE, Calif., Sept. 23, 2026 /PRNewswire/ -- GRAIL, Inc., a healthcare company whose mission is

A panel of outside experts advising the US FDA backed the ​safety of Grail's blood-based cancer dete

Baird analyst Catherine Schulte maintains GRAIL (NASDAQ:GRAL) with a Outperform and raises the pr

GRAIL (GRAL) stock surges >30% as FDA briefing notes on Galleri cancer test signal optimism ahead of

Grail Inc. (NASDAQ:GRAL) stock is surging on Monday after the FDA staff released an executive summar

Grail stock surges on favorable FDA briefing documents back its Galleri multi-cancer test ahead of t

Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular sessio

The US FDA's staff reviewers did not raise major concerns about the accuracy and safety of Grail's b

The biotech meets with the Food and Drug Administration this week for premarket approval of its land

U.S. stocks rose Monday, with Nasdaq up 1%. Critical Metals jumped 38% on Greenland deal news as tec

RBC initiated coverage of Grail with a Sector Perform rating and $84 target, citing Galleri’s potent

On Wednesday, GRAIL (NASDAQ:GRAL) discussed second-quarter financial results during its earnings cal

RBC Capital analyst Dan Leonard initiates coverage on GRAIL (NASDAQ:GRAL) with a Sector Perform r

GRAIL, Inc. (GRAL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

UBS analyst Doug Schenkel initiates coverage on GRAIL (NASDAQ:GRAL) with a Buy rating and announc

The FDA's advisory committee will meet on September 23 to review the PMA application for GRAIL&#

GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can

GRAIL (NASDAQ:GRAL) reported quarterly losses of $(2.56) per share which beat the analyst consensus

GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can

Mizuho analyst Bradley Bowers maintains GRAIL (NASDAQ:GRAL) with a Neutral and raises the price t

Goldman Sachs analyst Evie Koslosky initiates coverage on GRAIL (NASDAQ:GRAL) with a Neutral rati

TD Cowen analyst Dan Brennan maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target

Piper Sandler analyst David Westenberg maintains GRAIL (NASDAQ:GRAL) with a Neutral and raises th

GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can

Wall Street analysts changed outlook on top stocks. See rating changes on NKE, SMPL, WSR, NTNX, and

Top Wall Street analysts changed outlook on top names. Initiations & upgrades noted. For full ch

Mizuho analyst Bradley Bowers initiates coverage on GRAIL (NASDAQ:GRAL) with a Neutral rating and

Piper Sandler analyst David Westenberg initiates coverage on GRAIL (NASDAQ:GRAL) with a Neutral r

GRAIL stock rises after Epic partnership expands Galleri test access; trial shows Stage IV reduction

Integration Will Enable Approximately 450 Health Systems to Access the Galleri Test Results Within T

Guggenheim analyst Subbu Nambi maintains GRAIL (NASDAQ:GRAL) with a Buy and lowers the price targ